BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18419403)

  • 1. Strategies for herpes zoster vaccination of immunocompromised patients.
    Cohen JI
    J Infect Dis; 2008 Mar; 197 Suppl 2(Suppl 2):S237-41. PubMed ID: 18419403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varicella Virus Vaccination in the United States.
    Shaw J; Gershon AA
    Viral Immunol; 2018 Mar; 31(2):96-103. PubMed ID: 29173081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varicella and herpes zoster vaccines: WHO position paper, June 2014.
    Wkly Epidemiol Rec; 2014 Jun; 89(25):265-87. PubMed ID: 24983077
    [No Abstract]   [Full Text] [Related]  

  • 4. Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster.
    Gershon AA; Gershon MD; Shapiro ED
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S387-S397. PubMed ID: 34590140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective on live varicella vaccine.
    Gershon AA; Katz SL
    J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of live attenuated and recombinant/inactivated varicella zoster vaccines in people living with HIV: A systematic review.
    Carta V; Mangeri L; Tiecco G; Focà E; Quiros-Roldan E; De Francesco MA
    Hum Vaccin Immunother; 2024 Dec; 20(1):2341456. PubMed ID: 38650460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
    Willis ED; Woodward M; Brown E; Popmihajlov Z; Saddier P; Annunziato PW; Halsey NA; Gershon AA
    Vaccine; 2017 Dec; 35(52):7231-7239. PubMed ID: 29174682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?
    Gershon AA
    J Infect; 2017 Jun; 74 Suppl 1(Suppl 1):S27-S33. PubMed ID: 28646959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shingrix for Herpes Zoster: A Review.
    Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK
    Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.
    Horn J; Karch A; Damm O; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Hengel H; Greiner W; Mikolajczyk RT
    Hum Vaccin Immunother; 2016 Jul; 12(7):1766-76. PubMed ID: 26835890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
    Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
    PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Varicella vaccination: who should be vaccinated these days?].
    Hügle B; Suchowerskyj P; Schuster V
    MMW Fortschr Med; 2005 Feb; 147(8):31-2, 34-5. PubMed ID: 18441563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes Zoster Vaccines.
    Harbecke R; Cohen JI; Oxman MN
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunization of adults against varicella and herpes zoster].
    Hanslik T; Blanchon T; Alvarez FP
    Rev Med Interne; 2007 Mar; 28(3):166-72. PubMed ID: 17270316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.
    Bharucha T; Ming D; Breuer J
    Hum Vaccin Immunother; 2017 Aug; 13(8):1789-1797. PubMed ID: 28426274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine profile of herpes zoster (HZ/su) subunit vaccine.
    Cunningham AL; Heineman T
    Expert Rev Vaccines; 2017 Jul; 16(7):1-10. PubMed ID: 28486850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varicella zoster virus vaccines: effective, but concerns linger.
    Liesegang TJ
    Can J Ophthalmol; 2009 Aug; 44(4):379-84. PubMed ID: 19606157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.